Precision Business Insights
Portfolio

 

Research Reports

Global Bronchodilators Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Global Bronchodilators Market: By Drug Class (Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, Combination Drugs), By Route of Administration (Oral, Parenteral, Inhalation), By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Global bronchodilators market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.

 

Market Outline: Bronchodilators Market

Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to lungs.  These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting. Majorly used bronchodilators are include sympathomimetics, phosphodiesterase inhibitors, and anticholinergics among others.

 

Market Dynamics: Bronchodilators Market

Increase in the aging population coupled with rise in prevalence of various lung diseases such as asthma and COPD surge the global bronchodilators market. Moreover, rise in R&D expenditure for the development newer drugs, increase in geriatric population, environmental factors such as air pollution, rise in incidence of respiratory disorders in children, government initiation to improve awareness about the lung diseases, technological advancements of the inhalation devices, and rise in disposable income are propel the global bronchodilators market over the forecast years. However, stringent regulations for the product approval, high cost of products, adverse effects associated with the long term usage of drugs, and rise in awareness programs to prevent the respiratory disorders are restrain the growth of global bronchodilators market.

 

Market Scope: Bronchodilators Market

Bronchodilators market is segmented based on the drug class, route of administration, duration of action, disease type, and distribution channel

Based on the drug class, the market is segmented into the following:

  • Phosphodiesterase Inhibitors
  • Anticholinergics
  • Sympathomimetics
  • Non-Selective Adrenergic Agonists
  • Non-Selective Beta-2 Agonists
  • Selective Beta-2 Agonists
  • Combination Drugs

Based on route of administration, the market is segmented into the following:

  • Oral
  • Parenteral
  • Inhalation

Based on the disease type, the market is segmented into the following:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Regional Analysis:  Bronchodilators Market

Geographically, global bronchodilators market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America bronchodilators market is growing due to rise in R&D for the innovation of newer drugs, rise in prevalence of COPD and asthma, rise in demand for the combination therapies are anticipated to fuel the market. Europe bronchodilators market driven by increase in adoption of newer bronchodilators, rise in disposable income, and rise in awareness about the bronchodilators are spur the market. However, Asia Pacific bronchodilators market has a lucrative growth, attributed to large patient pool in India and China, grow in healthcare expenditure, and launch of newer drugs in Asia Pacific region are bolster the market over the forecast years.

 

Competition Assessment: Bronchodilators Market

Some of the players in the global bronchodilators market include:

  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

 

Notable Market Developments: Bronchodilators Market

  • In April 2016, AstraZeneca received FDA approval for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) used as a bronchodilator in COPD
  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Contact SalesTOLL FREE: +1-866-598-1553